Novo Nordisk A/S (NVO)
NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-market:
| Previous close | 107.84 |
| Open | 108.49 |
| Bid | 107.35 x 900 |
| Ask | 107.44 x 800 |
| Day's range | 107.29 - 108.98 |
| 52-week range | 78.71 - 122.16 |
| Volume | |
| Avg. volume | 1,513,501 |
| Market cap | 244.823B |
| Beta (5Y monthly) | 0.25 |
| PE ratio (TTM) | 35.36 |
| EPS (TTM) | 3.05 |
| Earnings date | N/A |
| Forward dividend & yield | 1.57 (1.46%) |
| Ex-dividend date | 25 Mar 2022 |
| 1y target est | 130.92 |
- Zacks
The Zacks Analyst Blog Highlights Bank of America, Novo Nordisk, Novartis, Analog Devices and Sony Group
Bank of America, Novo Nordisk, Novartis, Analog Devices and Sony Group have been included in this Analyst Blog.
- Zacks
Top Analyst Reports for Bank of America, Novo Nordisk, & Novartis
Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corporation (BAC), Novo Nordisk A/S (NVO), and Novartis AG (NVS).
- Motley Fool
Why This FDA Approval Is a Game Changer for Eli Lilly
Eli Lilly (NYSE: LLY) is a top healthcare company that continually finds new ways to grow and create value for its investors. One of the company's recent diabetes treatments has obtained approval from the U.S. Food and Drug Administration (FDA). On May 13, Eli Lilly announced that the FDA had approved Mounjaro (tirzepatide) to treat people with type 2 diabetes.
© 2022 Yahoo. All rights reserved.
